ClinicalTrials.gg
Not yet recruitingNCT05558267Updated Mar 12, 2026

Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease

An interventional study of Standard Table Salt and Salt Substitute in End Stage Kidney Disease, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
451st of 638
20 · median 48
Started
2027
with 3 others
No phase
287 of 765
28 open now
Primary completion
2027-06
later than 39 of 95 live
Registered
678th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 451st largest by planned enrollment of the 638 interventional ones that give a count, is one of 4 that started in 2027, is one of 287 with no phase, reaches primary completion later than 39 of the 95 other live ones, and was the 678th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration will be measured bi-weekly prior to HD each week during intervention. The primary endpoint will be the change in potassium from baseline. Additional measurements will include assessment of dietary intake, ambulatory blood pressure, occurrence of peri-dialytic symptoms, and per-dialytic vital signs.

03

Conditions studied

  • End Stage Kidney Disease

Keywords

  • Potassium-Containing Salt Substitute
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Receiving outpatient maintenance HD therapy.
  2. Age ≥ 21 years.
  3. Negative serum pregnancy test for women of child-bearing capacity. Childbearing capacity will be defined by report of menstruation within ≤ 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Currently incarcerated.
  2. Insufficient capacity for .
  3. Non-hemolyzed serum potassium concentration >6.0 mEq/L within ≤30 days.
  4. Unscheduled HD for hyperkalemia within ≤30 days.
  5. Attendance at ≤10 of last 13 scheduled OP HD sessions.
  6. Co-habiting family member with known hyperkalemia.
  7. Co-habiting family with ≥stage 3b chronic kidney disease or chronic kidney disease of unknown severity.
  8. \< 8.0 mg/dL.
  9. Use of other potassium supplements.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Standard Table Salt, then Salt Substitute

    The two intervention periods will last 16 days with a 19-day washout period in between. During the first 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table. Participants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing. In addition, participants will undergo standard of care hemodialysis (typically 3x/week) and have their blood chemistries measured according to the usual standard of care during the study.

    Dietary Supplement: Standard Table Salt · Dietary Supplement: Salt Substitute

  • Experimental
    Salt Substitute, then Standard Table Salt

    The two intervention periods will last 16 days with a 19-day washout period in between. During the first 16-day treatment period, participants will receive the Salt Substitute to use for cooking and as an additive at the table. Participants will then undergo a 19-day washout period. The second 16-day treatment period will immediately follow the washout period. During the second 16-day treatment period, participants will receive the Standard Table Salt to use for cooking and as an additive at the table. Participants will be encouraged to replace their use of regular salt with the Standard Table Salt and Salt Substitute. They will be encouraged to reduce their overall intake of salt throughout the study period. There are no restrictions or further instructions regarding timing or dosing. In addition, participants will undergo standard of care hemodialysis (typically 3x/week) and have their blood chemistries measured according to the usual standard of care during the study.

    Dietary Supplement: Standard Table Salt · Dietary Supplement: Salt Substitute

Interventions

  • Dietary supplementStandard Table Salt

    Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.

    Also known as: Morton Standard Table Salt

  • Dietary supplementSalt Substitute

    Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt. Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.

    Also known as: Morton Lite Salt

06

What researchers measure

Primary outcomes

  1. Change in Serum Potassium Concentration During First Treatment Period

    Serum potassium concentration expressed in milliequivalents per liter (mEq/L).

    Time frame: Day 1, Day 16

  2. Change in Serum Potassium Concentration During Second Treatment Period

    Serum potassium concentration expressed in mEq/L.

    Time frame: Day 36, Day 52

Secondary outcomes

  1. Number of Participants Presenting with Severe Hyperkalemia During First Treatment Period

    Severe hyperkalemia defined as pre-dialysis potassium levels greater than 6.5 mEq/L. The first treatment period spans from Day 1 to Day 16.

    Time frame: Up to Day 16

  2. Number of Participants Presenting with Severe Hyperkalemia During Second Treatment Period

    Severe hyperkalemia defined as pre-dialysis potassium levels greater than 6.5 mEq/L. The second treatment period spans from Day 36 to Day 52.

    Time frame: From Day 36 up to Day 52

  3. Number of Participants Presenting with Moderate Hyperkalemia

    Moderate hyperkalemia defined as pre-dialysis potassium levels greater than 6.0 mEq/L and less than 6.5 mEq/L.

    Time frame: Up to Day 52

  4. Mean Potassium Concentration During First Treatment Period

    Potassium concentration expressed in mEq/L. The first treatment period spans from Day 1 to Day 16.

    Time frame: Up to Day 16

  5. Mean Potassium Concentration During Second Treatment Period

    Potassium concentration expressed in mEq/L. The second treatment period spans from Day 36 to Day 52.

    Time frame: From Day 36 up to Day 52

  6. Change in Ambulatory Systolic Blood Pressure During First Treatment Period

    Ambulatory systolic blood pressure expressed in millimeters of mercury (mm Hg).

    Time frame: Day 1, Day 16

  7. Change in Ambulatory Systolic Blood Pressure During Second Treatment Period

    Ambulatory systolic blood pressure expressed in mm Hg.

    Time frame: Day 36, Day 52

  8. Mean Pre-Dialysis Systolic Blood Pressure During First Treatment Period

    Pre-dialysis systolic blood pressure expressed in mm Hg. The first treatment period spans from Day 1 to Day 16.

    Time frame: Up to Day 16

  9. Mean Pre-Dialysis Systolic Blood Pressure During Second Treatment Period

    Pre-dialysis systolic blood pressure expressed in mm Hg. The second treatment period spans from Day 36 to Day 52.

    Time frame: From Day 36 up to Day 52.

  10. Number of Participants Presenting with Intradialytic Hypotension

    Intradialytic hypotension defined as a systolic blood pressure of less than 100 mmHg or a systolic blood pressure decrease of greater than 10 mmHg, or a mean arterial pressure decrease of greater than 30 mmHg with or without symptoms.

    Time frame: Up to Day 52

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification, will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: David Charytan, MD MSc (David.charytan@Nyulangone.org). The protocol will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.charytan@Nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 5 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Sep 28, 2022
StartEst.
Jan 15, 2027
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05558267
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Jan 15, 2027 (estimated)
Primary completion
Jun 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

David Charytan, MD MSc
Contact
David.charytan@Nyulangone.org
617-935-1572
Zoe Rimler
Contact
Zoe.Rimler@nyulangone.org
631-357-1333
David Charytan, MD MSc
principal investigator · NYU Langone Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salt substitute

Start the discussion